Are natural killer cells superior CAR drivers?

References

• Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, Levine BL, Litchman M, Maude SL, Rheingold SR, et al.. T Cells engineered with a Chimeric Antigen Receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GvHd in children and adults with relapsed, refractory ALL. Blood 2013; 122:67
   Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; 122:4129 - 39; http://dx.doi.org/10.1182/blood-2013-08-519413; PMID: 24055823
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21:215 - 23; http://dx.doi.org/10.1016/j.coi.2009.02.009; PMID: 19327974
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; http://dx.doi.org/10.1126/scitranslmed.3002842; PMID: 21832238
   PubMed Web of Science ®Google Scholar
• Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, et al. Anti-CD123 Chimeric Antigen Receptor T cells (CART-123) provide a novel myeloablative conditioning regimen that eradicates human acute myeloid leukemia in preclinical models. Blood 2013; 122:143; PMID: 23690447
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843 - 51; http://dx.doi.org/10.1038/mt.2010.24; PMID: 20179677
   PubMed Web of Science ®Google Scholar
• Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010; 70:9053 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-10-2880; PMID: 20926399
   PubMed Web of Science ®Google Scholar
• Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. PLoS One 2007; 2:e326; http://dx.doi.org/10.1371/journal.pone.0000326; PMID: 17389917
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69:4010 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-08-3712; PMID: 19383914
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009; 33:1255 - 9; http://dx.doi.org/10.1016/j.leukres.2008.11.024; PMID: 19147228
   PubMed Web of Science ®Google Scholar
• Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100:1265 - 73; PMID: 12149207
   PubMed Web of Science ®Google Scholar
• Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, Wolfraim LA, Fujisaki H, Campana D, Chopas N, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther 2010; 17:147 - 54; http://dx.doi.org/10.1038/cgt.2009.61; PMID: 19745843
   PubMed Web of Science ®Google Scholar
• Imai C, Mihara K, Andreansky M, Nicholson IC, Pui C-H, Geiger TL, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18:676 - 84; http://dx.doi.org/10.1038/sj.leu.2403302; PMID: 14961035
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, Leung W, Campana D. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 2012; 14:830 - 40; http://dx.doi.org/10.3109/14653249.2012.671519; PMID: 22458956
   PubMed Web of Science ®Google Scholar
• Romanski A, Uherek C, Bug G, Muller T, Rossig C, Kampfmann M, Krossok N, Hoelzer D, Seifried E, Wels W, et al. Re-targeting of an NK cell line (NK-92) with specificity for CD19 efficiently kills human B-precursor leukemic cells. Blood 2004; 104:751a
   Web of Science ®Google Scholar
• Chu Y, Yahr A, Ayello J, van de Ven C, Zhou X, Cairo MS. Anti-CD20 Chimeric Antigen Receptor (CAR) modified expanded Natural Killer (NK) cells significantly mediate Burkitt Lymphoma (BL) regression and improve survival in human BL xenografted NSG mice. Blood 2013; 122:3263
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2:e26527; http://dx.doi.org/10.4161/onci.26527; PMID: 24404423
   PubMed Web of Science ®Google Scholar
• Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008; 57:411 - 23; http://dx.doi.org/10.1007/s00262-007-0383-3; PMID: 17717662
   PubMed Web of Science ®Google Scholar
• Yang S, Xin A, Brown RD, Ho J, Gibson J, Joshua DE, Wels W, Sze DM. Development of retargeted CD38-specific NK-92 cell line for potential anti-myeloma immunotherapy. [abstr] Blood 2005; 106:5104
   Web of Science ®Google Scholar
• Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, Kiessling R, Blankenstein T, Abken H, Charo J. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A 2008; 105:17481 - 6; http://dx.doi.org/10.1073/pnas.0804788105; PMID: 18987320
   PubMed Web of Science ®Google Scholar
• Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 2012; 16:569 - 81; http://dx.doi.org/10.1111/j.1582-4934.2011.01343.x; PMID: 21595822
   PubMed Web of Science ®Google Scholar
• Sahm C, Schönfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 2012; 61:1451 - 61; http://dx.doi.org/10.1007/s00262-012-1212-x; PMID: 22310931
   PubMed Web of Science ®Google Scholar
• Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther 2012; 19:84 - 100; http://dx.doi.org/10.1038/cgt.2011.66; PMID: 21979579
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2013; Forthcoming http://dx.doi.org/10.1038/leu.2013.279; PMID: 24067492
   PubMed Web of Science ®Google Scholar
• Koehne G, Guo HF, Trivedi D, Williams RY, O’Reilly RO, Cheung V. . Redirecting NK-cell cytolytic activity to solid tumors using chimeric scFv receptor gene-modified adoptive immunotherapy. ASCO Proc2001; 22: 175a.
   Google Scholar